EMA Authorised: Namuscla (Mexiletine hydrochloride) — Lupin Europe GmbH

View source ↗

Summary

The European Medicines Agency authorised Namuscla (mexiletine hydrochloride) for myotonic disorders under Lupin Europe GmbH, with orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myotonic Disorders

Drugs mentioned

• Namuscla (Mexiletine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Myotonic Disorders. MAH: Lupin Europe GmbH. Decision date: 27/11/2025. Orphan medicine